

# Joan Domingo Gispert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5341458/publications.pdf>

Version: 2024-02-01

208  
papers

6,245  
citations

81839

39  
h-index

95218

68  
g-index

224  
all docs

224  
docs citations

224  
times ranked

9590  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genotypic effects of <i>APOE</i> - $\epsilon$ 4 on resting-state connectivity in cognitively intact individuals support functional brain compensation. <i>Cerebral Cortex</i> , 2023, 33, 2748-2760.	1.6	5
2	Soundtrack of life: An fMRI study. <i>Behavioural Brain Research</i> , 2022, 418, 113634.	1.2	0
3	Spatial-Temporal Patterns of $\epsilon$ 2-Amyloid Accumulation. <i>Neurology</i> , 2022, 98, .	1.5	40
4	Age, sex and <i>APOE</i> - $\epsilon$ 4 modify the balance between soluble and fibrillar $\epsilon$ 2-amyloid in non-demented individuals: topographical patterns across two independent cohorts. <i>Molecular Psychiatry</i> , 2022, 27, 2010-2018.	4.1	9
5	Quantification of amyloid PET for future clinical use: a state-of-the-art review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3508-3528.	3.3	34
6	The protective gene dose effect of the <i>APOE</i> - $\epsilon$ 2 allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2022, 18, 1383-1395.	0.4	13
7	Impact of cerebral blood flow and amyloid load on SUVR bias. <i>EJNMMI Research</i> , 2022, 12, 29.	1.1	6
8	Brain alterations in the early Alzheimer's continuum with amyloid- $\epsilon$ 2, tau, glial and neurodegeneration CSF markers. <i>Brain Communications</i> , 2022, 4, .	1.5	12
9	Regional associations of white matter hyperintensities and early cortical amyloid pathology. <i>Brain Communications</i> , 2022, 4, .	1.5	9
10	The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. <i>NeuroImage: Clinical</i> , 2022, 35, 103106.	1.4	9
11	Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4567-4579.	3.3	16
12	Simulating the effect of cerebral blood flow changes on regional quantification of [ <sup>18</sup> F]flutemetamol and [ <sup>18</sup> F]florbetaben studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 579-589.	2.4	12
13	Nonlinear interaction between <i>APOE</i> - $\epsilon$ 4 allele load and age in the hippocampal surface of cognitively intact individuals. <i>Human Brain Mapping</i> , 2021, 42, 47-64.	1.9	12
14	Brain correlates of urban environmental exposures in cognitively unimpaired individuals at increased risk for Alzheimer's disease: A study on Barcelona's population. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12205.	1.2	7
15	Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals. <i>Journal of the American College of Cardiology</i> , 2021, 77, 888-898.	1.2	24
16	Visual assessment of [ <sup>18</sup> F]flutemetamol PET images can detect early amyloid pathology and grade its extent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2169-2182.	3.3	24
17	Differential associations of <i>APOE</i> - $\epsilon$ 2 and <i>APOE</i> - $\epsilon$ 4 alleles with PET-measured amyloid- $\epsilon$ 2 and tau deposition in older individuals without dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2212-2224.	3.3	29
18	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 46.	3.0	9

#	ARTICLE	IF	CITATIONS
19	Cerebral amyloid- $\beta^2$ load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's <i>continuum</i>. <i>Alzheimer's and Dementia</i> , 2021, 17, 788-800.	0.4	14
20	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2183-2199.	3.3	16
21	Management and Quality Control of Large Neuroimaging Datasets: Developments From the Barcelona $\beta$ eta Brain Research Center. <i>Frontiers in Neuroscience</i> , 2021, 15, 633438.	1.4	9
22	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204.	0.4	44
23	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 82.	3.0	14
24	Uncertainty analysis of MR-PET image registration for precision neuro-PET imaging. <i>NeuroImage</i> , 2021, 232, 117821.	2.1	8
25	Genetic Influences on Hippocampal Subfields. <i>Neurology: Genetics</i> , 2021, 7, e591.	0.9	8
26	Genetic Predisposition to Alzheimer's Disease Is Associated with Enlargement of Perivascular Spaces in Centrum Semiovale Region. <i>Genes</i> , 2021, 12, 825.	1.0	7
27	Cognitively unimpaired individuals with a low burden of $\beta^2$ pathology have a distinct CSF biomarker profile. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 134.	3.0	8
28	Parametric imaging of dual-time window [18F]flutemetamol and [18F]florbetaben studies. <i>NeuroImage</i> , 2021, 234, 117953.	2.1	7
29	Amyloid- $\beta^2$ positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. <i>Neurobiology of Aging</i> , 2021, 104, 24-31.	1.5	13
30	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 135.	3.0	30
31	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 119-128.	1.2	3
32	CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET. <i>Neurology</i> , 2021, 97, e2065-e2078.	1.5	40
33	Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECF-SEOR Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3118-3127.	0.8	73
34	Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Environment International</i> , 2021, 157, 106864.	4.8	40
35	Comparative Analysis of Different Definitions of Amyloid- $\beta^2$ Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer. <i>Journal of Prevention of Alzheimer's Disease</i> , 2021, 8, 1-10.	1.5	9
36	p-tau <sub>235</sub> : a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e15098.	3.3	30

#	ARTICLE	IF	CITATIONS
37	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	4.5	204
38	Single-cell Transcriptional Changes in Neurodegenerative Diseases. <i>Neuroscience</i> , 2021, 479, 192-205.	1.1	11
39	Quantitative amyloid PET in the AMYPAD diagnostic and patient management study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
40	Association between telomere length and cognitive function among cognitively unimpaired individuals at risk of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
41	Higher levels of the astrocytic marker CSF YKL40 are associated with better memory performance only in amyloid- $\beta$ positive individuals with subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
42	Midlife subclinical atherosclerosis and cardiovascular risk factors linked to hypometabolism in Alzheimer's disease relevant regions. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
43	Brain structural alterations in cognitively unimpaired individuals with discordant amyloid- $\beta$ PET and CSF A $\beta$ 42 status: Findings using machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
44	Cognitive function and neuroimaging correlates in a subjective cognitive decline population within a multimodal intervention supplemented with green tea extract (PENSA Study): Preliminary results of a voxel-based morphometry study. <i>Alzheimer's and Dementia</i> , 2021, 17, e055894.	0.4	1
45	Sex differences in genetic susceptibility of hippocampal subfields: A polygenic association study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
46	Prediction of amyloid pathology in cognitively unimpaired individuals using structural MRI. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
47	Machine learning on combined neuroimaging and plasma biomarkers for triaging participants of secondary prevention trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
48	Imaging neurodegeneration markers are associated with multiple pathophysiological mechanisms in the early stages of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
49	Subjective cognitive decline is associated with higher anxiety and depression during the COVID-19 related confinement. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
50	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
51	Optimal parametric imaging methods for dual-time-window [ <sup>18</sup> F]flutemetamol and [ <sup>18</sup> F]florbetaben PET studies. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
52	Evaluating robustness of the Centiloid scale against variations in amyloid PET image resolution. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	3
53	Synergistic effects of CSF A $\beta$ 42 and $\tau$ on functional resting-state connectivity in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
54	Cross-sectional associations between sleep quality reports and core Alzheimer's disease biomarkers in cognitively unimpaired adults from the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
55	Data-driven approach for early detection of pathological pathways in middle-aged adults with family history of sporadic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
56	Structural, metabolic and cognitive characteristics of cognitively unimpaired subjects with mismatching $\beta$ -amyloid biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
57	Associations between iron deposition in the brain and grey matter volumes in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
58	Neuroimaging-derived phenotypes in the European Prevention of Alzheimer Dementia (EPAD) Cohort Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
59	Association of body mass index with brain structure and biomarkers of inflammation in cognitively unimpaired middle-aged adults with and without evidence of $\beta$ -amyloid pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
60	Current status and quantitative results of the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
61	Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
62	Sex, caregiver status and amyloid positivity predict increased anxiety and depression during the COVID-19-related confinement. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
63	Shared Latent Structures Between Imaging Features and Biomarkers in Early Stages of Alzheimer's Disease: A Predictive Study. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 365-376.	3.9	1
64	Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. <i>Brain Imaging and Behavior</i> , 2020, 14, 2012-2023.	1.1	40
65	Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 4.	3.0	53
66	White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants. <i>Human Brain Mapping</i> , 2020, 41, 1309-1322.	1.9	27
67	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.5	55
68	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1413-1422.	1.2	4
69	Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. <i>Neurology</i> , 2020, 95, e2065-e2074.	1.5	3
70	Projection to Latent Spaces Disentangles Pathological Effects on Brain Morphology in the Asymptomatic Phase of Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 648.	1.1	6
71	Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE- $\epsilon$ 4 in middle-age cognitively unimpaired individuals from the ALFA study. <i>Brain Structure and Function</i> , 2020, 225, 2331-2345.	1.2	5
72	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A $\beta$ pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921.	3.3	202

#	ARTICLE	IF	CITATIONS
73	Subjective cognitive decline correlates with medial temporal lobe and hippocampal subfield volumetry in cognitively unimpaired participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e043520.	0.4	0
74	Amyloid $\beta$ , tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044444.	0.4	0
75	Emerging beta-amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. <i>Alzheimer's and Dementia</i> , 2020, 16, e044466.	0.4	1
76	Genetically predicted telomere length and Alzheimer's disease endophenotypes: A Mendelian randomization study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044720.	0.4	0
77	The effect of physical activity on CSF biomarkers of Alzheimer's disease differs between men and women. <i>Alzheimer's and Dementia</i> , 2020, 16, e044722.	0.4	0
78	Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044733.	0.4	0
79	Higher fronto-parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. <i>Alzheimer's and Dementia</i> , 2020, 16, e044780.	0.4	0
80	Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044808.	0.4	0
81	PENSA study: Study design, recruitment profiles and participant inclusion in multimodal intervention studies. <i>Alzheimer's and Dementia</i> , 2020, 16, e045074.	0.4	0
82	APOE $\epsilon$ 4 shapes temporo-parietal network properties in middle-aged, cognitively unimpaired individuals: A graph theory analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e045092.	0.4	0
83	Weight loss predicts Alzheimer's disease biomarker positivity in cognitively unimpaired middle-aged adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e045137.	0.4	0
84	Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. <i>Alzheimer's and Dementia</i> , 2020, 16, e045171.	0.4	0
85	Incidence of subjective cognitive decline is associated with amyloid $\beta$ pathology, whereas stability relates to neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e045293.	0.4	0
86	Harmonization of amyloid PET scans minimizes the impact of reconstruction parameters on centiloid values. <i>Alzheimer's and Dementia</i> , 2020, 16, e045294.	0.4	2
87	Amyloid-positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. <i>Alzheimer's and Dementia</i> , 2020, 16, e045715.	0.4	0
88	The Barcelonabeta dementia prevention research clinic: Study design, recruitment profiles and inclusion in prevention studies – An update. <i>Alzheimer's and Dementia</i> , 2020, 16, e045800.	0.4	0
89	Impact of APOE $\epsilon$ 4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , 2020, 16, e045828.	0.4	1
90	ALFA+: A cohort study to understand and model the preclinical stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045935.	0.4	0

#	ARTICLE	IF	CITATIONS
91	Quantitative informant and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE $\epsilon$ 4. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12127.	1.2	6
92	Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i> . <i>Alzheimer's and Dementia</i> , 2020, 16, 1358-1371.	0.4	120
93	APOE- $\epsilon$ 4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. <i>Cerebral Cortex</i> , 2020, 30, 4110-4120.	1.6	7
94	NeAT: a Nonlinear Analysis Toolbox for Neuroimaging. <i>Neuroinformatics</i> , 2020, 18, 517-530.	1.5	0
95	Impact of urban environmental exposures on cognitive performance and brain structure of healthy individuals at risk for Alzheimer's dementia. <i>Environment International</i> , 2020, 138, 105546.	4.8	69
96	The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. <i>Neurobiology of Aging</i> , 2020, 95, 104-114.	1.5	15
97	Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation. <i>Brain</i> , 2020, 143, 976-992.	3.7	16
98	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, 750-758.	0.4	29
99	Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 72.	3.0	23
100	Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies. <i>EJNMMI Research</i> , 2019, 9, 32.	1.1	31
101	Multipurpose Virtual Reality Environment for Biomedical and Health Applications. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2019, 27, 1511-1520.	2.7	15
102	Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for SMALL-CELL LUNG Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S35-S36.	0.4	17
103	Interactive effect of age and APOE- $\epsilon$ 4 allele load on white matter myelin content in cognitively normal middle-aged subjects. <i>NeuroImage: Clinical</i> , 2019, 24, 101983.	1.4	30
104	Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 12.	3.0	46
105	APOE- $\epsilon$ 4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals. <i>NeuroImage: Clinical</i> , 2019, 23, 101818.	1.4	18
106	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 27.	3.0	82
107	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101777.	1.4	29
108	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. <i>NeuroImage: Clinical</i> , 2019, 23, 101801.	1.4	26

#	ARTICLE	IF	CITATIONS
109	The Crus exhibits stronger functional connectivity with executive network nodes than with the default mode network. <i>Brain</i> , 2018, 141, e24-e24.	3.7	3
110	Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. <i>NeuroImage: Clinical</i> , 2018, 19, 190-201.	1.4	16
111	The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1067-1077.	1.2	19
112	Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid- $\beta$ and Tau. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1575-1587.	1.2	25
113	Learning non-linear patch embeddings with neural networks for label fusion. <i>Medical Image Analysis</i> , 2018, 44, 143-155.	7.0	21
114	Effects of <i>APOE</i> $\epsilon$ <sub>4</sub> allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 902-912.	0.4	98
115	Higher prevalence of cerebral white matter hyperintensities in homozygous <i>APOE</i> $\epsilon$ <sub>4</sub> allele carriers aged 45-75: Results from the ALFA study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 250-261.	2.4	29
116	P2-505: REGIONAL DISTRIBUTION OF WHITE MATTER HYPERINTENSITY CORRELATES WITH COGNITION IN THE ALFA COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P925.	0.4	4
117	Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 123.	3.0	73
118	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.	3.0	46
119	Episodic memory and executive functions in cognitively healthy individuals display distinct neuroanatomical correlates which are differentially modulated by aging. <i>Human Brain Mapping</i> , 2018, 39, 4565-4579.	1.9	32
120	Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 181-191.	1.2	15
121	MRI-Based Screening of Preclinical Alzheimer's Disease for Prevention Clinical Trials. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1099-1112.	1.2	18
122	White matter microstructure is altered in cognitively normal middle-aged <i>APOE</i> $\epsilon$ <sub>4</sub> homozygotes. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 48.	3.0	43
123	Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies. <i>Methods in Molecular Biology</i> , 2018, 1750, 165-184.	0.4	0
124	The <i>APOE</i> $\epsilon$ <sub>4</sub> genotype modulates CSF <i>YKL</i> $\epsilon$ <sub>40</sub> levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of <i>sTREM2</i> . <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 50-59.	1.2	36
125	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	1.2	10
126	Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer's disease: a cross-sectional analysis from the ALFA (Alzheimer and Families) project. <i>BMJ Open</i> , 2017, 7, e013215.	0.8	28



#	ARTICLE	IF	CITATIONS
127	Changes in cerebral [18F]-FDG uptake induced by acute alcohol administration in a rat model of alcoholism. Behavioural Brain Research, 2017, 327, 29-33.	1.2	11
128	A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease. NeuroImage: Clinical, 2017, 16, 343-354.	1.4	73
129	Characterization of the Biodistribution and Systemic Absorption of TT-173, a New Hemostatic Agent of Recombinant Human Tissue Factor, Using Radiolabeling with 18F. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 583-592.	0.6	3
130	[P1â€“395]: AMYPAD: A EUROPEAN PUBLICâ€“PRIVATE PARTNERSHIP TO INVESTIGATE THE VALUE OF Î²â€“AMYLOID BRAIN SCANS AS A DIAGNOSTIC AND THERAPEUTIC MARKER FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P420.	0.4	1
131	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in earlyâ€“stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	3.3	392
132	Psychometric Properties of the Memory Binding Test: Test-Retest Reliability and Convergent Validity. Journal of Alzheimer's Disease, 2016, 50, 999-1010.	1.2	26
133	The Memory Binding Test: Development of Two Alternate Forms into Spanish and Catalan. Journal of Alzheimer's Disease, 2016, 52, 283-293.	1.2	23
134	The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 82-92.	1.8	97
135	Modeling practice effects in healthy middleâ€“aged participants of the Alzheimer and Families parent cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 149-158.	1.2	6
136	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1259-1272.	0.4	86
137	Environment and Brain Development: Challenges in the Global Context. Neuroepidemiology, 2016, 46, 79-82.	1.1	17
138	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiology of Aging, 2016, 38, 47-55.	1.5	54
139	Reference Data of the Spanish Memory Binding Test in a Midlife Population from the ALFA STUDY (Alzheimerâ€™s and Family). Journal of Alzheimer's Disease, 2015, 48, 613-625.	1.2	18
140	Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype. Neurobiology of Aging, 2015, 36, 2687-2701.	1.5	46
141	Novel methodology for labelling mesoporous silica nanoparticles using the 18F isotope and their in vivo biodistribution by positron emission tomography. Journal of Nanoparticle Research, 2015, 17, 1.	0.8	9
142	Diazepam and Jacobson's Progressive Relaxation Show Similar Attenuating Short-Term Effects on Stress-Related Brain Glucose Consumption. European Psychiatry, 2015, 30, 187-192.	0.1	10
143	Relationships between serotonergic and cannabinoid system in depressiveâ€“like behavior: a <scp>PET</scp> study with [ <sup>11</sup> C]â€“DASB</scp>. Journal of Neurochemistry, 2014, 130, 126-135.	2.1	31
144	Assessing Lung Inflammation After Nanoparticle Inhalation Using 2-deoxy-2-[18F]fluoro-d-glucose Positron Emission Tomography Imaging. Molecular Imaging and Biology, 2014, 16, 264-273.	1.3	6

#	ARTICLE	IF	CITATIONS
145	Efficient cysteine labelling of peptides with N-succinimidyl 4-[ <sup>18</sup> F]fluorobenzoate: stability study and in vivo biodistribution in rats by positron emission tomography (PET). RSC Advances, 2013, 3, 8028.	1.7	5
146	In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. Neurobiology of Aging, 2013, 34, 1790-1798.	1.5	69
147	Erythrocytes labeled with [ <sup>18</sup> F]SFB as an alternative to radioactive CO for quantification of blood volume with PET. Contrast Media and Molecular Imaging, 2013, 8, 375-381.	0.4	9
148	A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells. Clinical Cancer Research, 2013, 19, 6787-6801.	3.2	80
149	The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study. Journal of Alzheimer's Disease, 2013, 36, 67-77.	1.2	53
150	Optimization of [ <sup>11</sup> C]Raclopride Positron Emission Tomographic Rat Studies: Comparison of Methods for Image Quantification. Molecular Imaging, 2013, 12, 7290.2012.00040.	0.7	1
151	Comparison of the Performance Evaluation of the MicroPET R4 Scanner According to NEMA Standards NU 4-2008 and NU 2-2001. IEEE Transactions on Nuclear Science, 2012, 59, 1879-1886.	1.2	9
152	In Vivo Biodistribution of Amino-Functionalized Ceria Nanoparticles in Rats Using Positron Emission Tomography. Molecular Pharmaceutics, 2012, 9, 3543-3550.	2.3	55
153	Synthesis and In Vivo Evaluation of the Biodistribution of a [ <sup>18</sup> F]-Labeled Conjugate Gold-Nanoparticle-Peptide with Potential Biomedical Application. Bioconjugate Chemistry, 2012, 23, 399-408.	1.8	100
154	In vivo molecular imaging of the GABA/benzodiazepine receptor complex in the aged rat brain. Neurobiology of Aging, 2012, 33, 1457-1465.	1.5	11
155	Gaba and serotonin molecular neuroimaging in essential tremor: A clinical correlation study. Parkinsonism and Related Disorders, 2012, 18, 876-880.	1.1	50
156	β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nature Medicine, 2012, 18, 892-901.	15.2	336
157	Rapid and high-yielding cysteine labelling of peptides with N-succinimidyl 4-[ <sup>18</sup> F]fluorobenzoate. Chemical Communications, 2012, 48, 6118.	2.2	12
158	Positron emission tomography with <sup>11</sup> C-flumazenil in the rat shows preservation of binding sites during the acute phase after 2h-transient focal ischemia. Neuroscience, 2011, 182, 208-216.	1.1	21
159	Biodistribution of Amino-Functionalized Diamond Nanoparticles. <i>In Vivo</i> Studies Based on [ <sup>18</sup> F] Radionuclide Emission. ACS Nano, 2011, 5, 5552-5559.	7.3	138
160	Positron Emission Tomographic Imaging of the Cannabinoid Type 1 Receptor System with [ <sup>11</sup> C]OMAR ([ <sup>11</sup> C]JHU75528): Improvements in Image Quantification Using Wild-Type and Knockout Mice. Molecular Imaging, 2011, 10, 7290.2011.00019.	0.7	7
161	Fronto-limbic dysfunction in borderline personality disorder: A <sup>18</sup> F-FDG positron emission tomography study. Journal of Affective Disorders, 2011, 131, 260-267.	2.0	50
162	[ <sup>11</sup> C]-DASB microPET imaging in the aged rat: Frontal and meso-thalamic increases in serotonin transporter binding. Experimental Gerontology, 2011, 46, 1020-1025.	1.2	8

#	ARTICLE	IF	CITATIONS
163	Simultaneous Dual-tracer PET Imaging of the Rat Brain and its Application in the Study of Cerebral Ischemia. <i>Molecular Imaging and Biology</i> , 2011, 13, 500-510.	1.3	19
164	Evaluation of Hypoxic Tissue Dynamics with 18F-FMISO PET in a Rat Model of Permanent Cerebral Ischemia. <i>Molecular Imaging and Biology</i> , 2011, 13, 558-564.	1.3	7
165	Biodistribution and Radiation Dosimetry of the Glycine Transporter-1 Ligand 11C-GSK931145 Determined from Primate and Human Whole-Body PET. <i>Molecular Imaging and Biology</i> , 2011, 13, 776-784.	1.3	13
166	Variations in the shape of the frontobasal brain region in obsessive-compulsive disorder. <i>Human Brain Mapping</i> , 2011, 32, 1100-1108.	1.9	14
167	A 18F-fluorodeoxyglucose MicroPET Imaging Study to Assess Changes in Brain Glucose Metabolism in a Rat Model of Surgery-induced Latent Pain Sensitization. <i>Anesthesiology</i> , 2011, 115, 1072-1083.	1.3	22
168	Comparison of positron emission tomography (PET) and computed tomography (CT) for better target volume definition in radiation therapy planning. <i>Clinical and Translational Oncology</i> , 2010, 12, 367-373.	1.2	9
169	Enhanced neural activity in frontal and cerebellar circuits after cognitive training in children with attention-deficit/hyperactivity disorder. <i>Human Brain Mapping</i> , 2010, 31, 1942-1950.	1.9	64
170	Central and peripheral consequences of the chronic blockade of CB <sub>1</sub> cannabinoid receptor with rimonabant or taranabant. <i>Journal of Neurochemistry</i> , 2010, 112, 1338-13351.	2.1	24
171	Dopamine D4 receptors modulate brain metabolic activity in the prefrontal cortex and cerebellum at rest and in response to methylphenidate. <i>European Journal of Neuroscience</i> , 2010, 32, 668-676.	1.2	26
172	Cerebellar neurometabolite abnormalities in pediatric attention/deficit hyperactivity disorder: A proton MR spectroscopic study. <i>Neuroscience Letters</i> , 2010, 470, 60-64.	1.0	29
173	The effects of aging on dopaminergic neurotransmission: a microPET study of [11C]-raclopride binding in the aged rodent brain. <i>Neuroscience</i> , 2010, 171, 1283-1286.	1.1	18
174	An evaluation of simultaneous dual-tracer technique for PET static studies. , 2009, , .		0
175	Comparison of NEMA NU 4-2008 vs NEMA NU 2-2001 for the performance evaluation of the microPET R4 system. , 2009, , .		5
176	Depressed Glucose Consumption at Reperfusion following Brain Ischemia does not Correlate with Mitochondrial Dysfunction and Development of Infarction: An in vivo Positron Emission Tomography Study. <i>Current Neurovascular Research</i> , 2009, 6, 82-88.	0.4	23
177	Automated Method for Small-Animal PET Image Registration with Intrinsic Validation. <i>Molecular Imaging and Biology</i> , 2009, 11, 107-113.	1.3	29
178	Ventro-Striatal Reductions Underpin Symptoms of Hyperactivity and Impulsivity in Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2009, 66, 972-977.	0.7	83
179	Partial volume correction using an energy multiresolution analysis. , 2009, , .		0
180	New method for routine production of L- <sup>11</sup> C-methionine: <i>in loop</i> synthesis. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2008, 51, 83-86.	0.5	29

#	ARTICLE	IF	CITATIONS
181	Differences in response to food stimuli in a rat model of obesity: in-vivo assessment of brain glucose metabolism. <i>International Journal of Obesity</i> , 2008, 32, 1171-1179.	1.6	42
182	Assessment of SPM in Perfusion Brain SPECT Studies. A Numerical Simulation Study Using Bootstrap Resampling Methods. <i>IEEE Transactions on Biomedical Engineering</i> , 2008, 55, 1849-1853.	2.5	11
183	Differential abnormalities of the head and body of the caudate nucleus in attention deficit-hyperactivity disorder. <i>Psychiatry Research - Neuroimaging</i> , 2008, 163, 270-278.	0.9	34
184	Differential clinical, structural and P300 parameters in schizophrenia patients resistant to conventional neuroleptics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 257-266.	2.5	29
185	Effect of anatomical variability, reconstruction algorithms and scattered photons on the SPM output of brain PET studies. <i>NeuroImage</i> , 2008, 39, 1121-1128.	2.1	9
186	Monitoring Gene Therapy by External Imaging of mRNA: Pilot Study on Murine Erythropoietin. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 612-618.	1.0	19
187	Pediatric OCD structural brain deficits in conflict monitoring circuits: A voxel-based morphometry study. <i>Neuroscience Letters</i> , 2007, 421, 218-223.	1.0	80
188	Impact of ventricular enlargement on the measurement of metabolic activity in spatially normalized PET. <i>NeuroImage</i> , 2007, 35, 748-758.	2.1	17
189	Imaging Brain Inflammation with [ <sup>11</sup> C]PK11195 by PET and Induction of the Peripheral-Type Benzodiazepine Receptor after Transient Focal Ischemia in Rats. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1975-1986.	2.4	137
190	Dopaminergic deficiency in mice with reduced levels of the dual-specificity tyrosine-phosphorylated and regulated kinase 1A, <i>Dyrk1A</i> +/??. <i>Genes, Brain and Behavior</i> , 2007, 6, 569-578.	1.1	25
191	Hypofrontality in men with first-episode psychosis. <i>British Journal of Psychiatry</i> , 2005, 186, 203-208.	1.7	34
192	Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2005, 20, 13-18.	0.9	21
193	The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. <i>Journal of Neurochemistry</i> , 2005, 92, 798-806.	2.1	241
194	Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. <i>Psychopharmacology</i> , 2005, 178, 17-26.	1.5	65
195	ROC evaluation of statistical wavelet-based analysis of brain activation in [ <sup>15</sup> O]-H <sub>2</sub> O PET scans. <i>NeuroImage</i> , 2005, 24, 763-770.	2.1	5
196	Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene. <i>NeuroImage</i> , 2005, 27, 1002-1006.	2.1	46
197	Global and regional gray matter reductions in ADHD: A voxel-based morphometric study. <i>Neuroscience Letters</i> , 2005, 389, 88-93.	1.0	241
198	N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. <i>Schizophrenia Research</i> , 2005, 73, 209-219.	1.1	58

#	ARTICLE	IF	CITATIONS
199	Method for bias field correction of brain T1-weighted magnetic resonance images minimizing segmentation error. Human Brain Mapping, 2004, 22, 133-144.	1.9	65
200	Cerebral metabolic patterns in chronic and recent-onset schizophrenia. Psychiatry Research - Neuroimaging, 2003, 122, 125-135.	0.9	53
201	Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia. Psychiatry Research - Neuroimaging, 2003, 124, 163-175.	0.9	34
202	Cerebral metabolism and risperidone treatment in schizophrenia. Schizophrenia Research, 2003, 60, 1-7.	1.1	41
203	Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. NeuroImage, 2003, 19, 601-612.	2.1	125
204	Association between relative temporal and prefrontal sulcal cerebrospinal fluid and illness duration in schizophrenia. Schizophrenia Research, 2002, 58, 305-312.	1.1	21
205	Multimodal neuroimaging studies and neurodevelopment and neurodegeneration hypotheses of schizophrenia. Neurotoxicity Research, 2002, 4, 437-451.	1.3	5
206	<title>Multimodality image quantification using the Talairach grid</title>. , 2001, , .		28
207	<title>Statistical segmentation of multidimensional brain datasets</title>. , 2001, , .		11
208	Inhomogeneity correction of magnetic resonance images by minimization of intensity overlapping. , 0, , .		3